GTSM:4747

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Johnson Chemical Pharmaceutical Works

Executive Summary

Johnson Chemical Pharmaceutical Works Co., Ltd. More Details


Snowflake Analysis

Excellent balance sheet average dividend payer.

Share Price & News

How has Johnson Chemical Pharmaceutical Works's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4747 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: 4747's weekly volatility (1%) has been stable over the past year.


Market Performance


7 Day Return

0.5%

4747

-0.9%

TW Pharmaceuticals

2.0%

TW Market


1 Year Return

-6.2%

4747

31.8%

TW Pharmaceuticals

31.2%

TW Market

Return vs Industry: 4747 underperformed the TW Pharmaceuticals industry which returned 31.8% over the past year.

Return vs Market: 4747 underperformed the TW Market which returned 31.2% over the past year.


Shareholder returns

4747IndustryMarket
7 Day0.5%-0.9%2.0%
30 Day-1.5%-8.0%10.6%
90 Day-1.1%-15.2%22.8%
1 Year-2.1%-6.2%34.1%31.8%35.8%31.2%
3 Year4.1%-8.3%39.5%31.9%58.3%40.5%
5 Year12.8%-9.7%10.5%2.0%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is Johnson Chemical Pharmaceutical Works's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Johnson Chemical Pharmaceutical Works undervalued compared to its fair value and its price relative to the market?

15.3x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 4747 (NT$36.35) is trading above our estimate of fair value (NT$34.99)

Significantly Below Fair Value: 4747 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 4747 is good value based on its PE Ratio (15.2x) compared to the TW Pharmaceuticals industry average (17.9x).

PE vs Market: 4747 is good value based on its PE Ratio (15.2x) compared to the TW market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4747's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4747 is good value based on its PB Ratio (1.3x) compared to the TW Pharmaceuticals industry average (2.1x).


Next Steps

Future Growth

How is Johnson Chemical Pharmaceutical Works forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Johnson Chemical Pharmaceutical Works has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Johnson Chemical Pharmaceutical Works performed over the past 5 years?

1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4747 has a high level of non-cash earnings.

Growing Profit Margin: 4747's current net profit margins (16.1%) are higher than last year (14.8%).


Past Earnings Growth Analysis

Earnings Trend: 4747's earnings have grown by 1.1% per year over the past 5 years.

Accelerating Growth: 4747's earnings growth over the past year (17.8%) exceeds its 5-year average (1.1% per year).

Earnings vs Industry: 4747 earnings growth over the past year (17.8%) underperformed the Pharmaceuticals industry 23.3%.


Return on Equity

High ROE: 4747's Return on Equity (8.5%) is considered low.


Next Steps

Financial Health

How is Johnson Chemical Pharmaceutical Works's financial position?


Financial Position Analysis

Short Term Liabilities: 4747's short term assets (NT$536.0M) exceed its short term liabilities (NT$244.9M).

Long Term Liabilities: 4747's short term assets (NT$536.0M) exceed its long term liabilities (NT$1.3M).


Debt to Equity History and Analysis

Debt Level: 4747's debt to equity ratio (17.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 4747's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 4747's debt is well covered by operating cash flow (58.2%).

Interest Coverage: 4747 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Johnson Chemical Pharmaceutical Works's current dividend yield, its reliability and sustainability?

4.92%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4747's dividend (4.95%) is higher than the bottom 25% of dividend payers in the TW market (2.09%).

High Dividend: 4747's dividend (4.95%) is low compared to the top 25% of dividend payers in the TW market (5.15%).


Stability and Growth of Payments

Stable Dividend: 4747's dividends per share have been stable in the past 10 years.

Growing Dividend: 4747's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (75.2%), 4747's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.0yrs

Average management tenure


CEO

P. Huang

22yrs

Tenure

Mr. P.H Huang serves as Chairman & Chief Executive Officer at Johnson Chemical Pharmaceutical Works Co., Ltd. Mr. Huang began his career with JCP in 1972 as a sales assistant, and subsequently served in a ...


Leadership Team

NamePositionTenureCompensationOwnership
P. Huang
Chairman & CEO22yrsno datano data
Grace Chen
Finance Director7yrsno datano data
Weike Lin
Sales Director11yrsno datano data
Guo An Liao
Deputy General Manager and Directorno datano datano data
Peter Lin
Chief Research Officerno datano datano data

11.0yrs

Average Tenure

Experienced Management: 4747's management team is seasoned and experienced (11 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Johnson Chemical Pharmaceutical Works Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Johnson Chemical Pharmaceutical Works Co., Ltd.
  • Ticker: 4747
  • Exchange: GTSM
  • Founded: 1966
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$1.099b
  • Shares outstanding: 30.02m
  • Website: https://www.jcpjohnson.com.tw

Number of Employees


Location

  • Johnson Chemical Pharmaceutical Works Co., Ltd.
  • 31, San Ho Road
  • Sec. 4
  • New Taipei City
  • 241
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4747GTSM (Taipei Exchange)YesCommon StockTWTWDJan 2010

Biography

Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures and sells pharmaceutical materials and products in Taiwan. The company offers its products in various therapeutic areas, including central nervo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 17:17
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.